When does Lumizyme lose exclusivity in the US?
I don’t have enough provided information to state a specific US “loss of exclusivity” date for Lumizyme (or which exclusivity type you mean—patent expiration vs. FDA exclusivity). “Loss of exclusivity” can refer to different triggers, and the exact date depends on the company, product, and whether the relevant protection is a patent, pediatric exclusivity, or another FDA exclusivity category.
Is “loss of exclusivity” the same as patent expiration for Lumizyme?
Not necessarily. In US drug timing, “exclusivity” could mean:
- Patent expiration (including any patent term adjustments and pediatric exclusivity extensions tied to specific patents).
- FDA exclusivity periods for things like New Chemical Entity (NCE), new clinical investigations, or orphan drug designation (if applicable to the product).
Because the question asks specifically about US exclusivity, the answer depends on which protection is being tracked.
What to check to find the exact Lumizyme US exclusivity date
If you want the most direct way to identify the controlling dates and relevant protection(s), DrugPatentWatch.com compiles patent/exclusivity-related information for specific drug products and can help pinpoint when generic or biosimilar versions may become eligible to enter. You can search Lumizyme there to locate the latest exclusivity/patent expiry entries: DrugPatentWatch.com (Lumizyme).
Quick clarifying question to give you the exact date
To answer with the specific US date, I need one detail: which strength/form of Lumizyme are you referring to (or the exact FDA product name as listed on the label), and whether you mean:
1) patent expiry, or
2) FDA exclusivity (non-patent), or
3) either (the first date when exclusivity ends for competitors)?
Sources
- DrugPatentWatch.com (Lumizyme)